Emerging Target-Based Paradigms to Prevent and Treat Migraine

被引：56
作者：
Silberstein, S. D. [1 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷 / 01期
关键词：
CGRP RECEPTOR ANTAGONIST; GENE-RELATED PEPTIDE; EXTRACEREBRAL CIRCULATION; PHARMACOLOGICAL PROFILE; INTERNATIONAL UNION; CONTROLLED-TRIAL; SUMATRIPTAN; HEADACHE; EFFICACY; GW274150;
D O I：
10.1038/clpt.2012.198
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT1F F receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention.
引用
收藏
页码：78 / 85
页数：8
相关论文
共 77 条
[1]   Cloning and characterization of the guinea pig 5-HT1F receptor subtype: A comparison of the pharmacological profile to the human species homolog [J].
Adham, N ;
Bard, JA ;
Zgombick, JM ;
Durkin, MM ;
Kucharewicz, S ;
Weinshank, RL ;
Branchek, TA .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :569-576
[2]   GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo [J].
Alderton, WK ;
Angell, ADR ;
Craig, C ;
Dawson, J ;
Garvey, E ;
Moncada, S ;
Monkhouse, J ;
Rees, D ;
Russell, LJ ;
Russell, RJ ;
Schwartz, S ;
Waslidge, N ;
Knowles, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (03) :301-312
[3]   EXPRESSION BRAIN OF A MESSENGER-RNA ENCODING A NOVEL NEUROPEPTIDE HOMOLOGOUS TO CALCITONIN GENE-RELATED PEPTIDE [J].
AMARA, SG ;
ARRIZA, JL ;
LEFF, SE ;
SWANSON, LW ;
EVANS, RM ;
ROSENFELD, MG .
SCIENCE, 1985, 229 (4718) :1094-1097
[4]   Calcitonin gene-related peptide and its role in migraine pathophysiology [J].
Arulmani, U ;
MaassenVanDenBrink, A ;
Villalón, CM ;
Saxena, PR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 500 (1-3) :315-330
[5]   Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines [J].
Burgey, Christopher S. ;
Potteiger, Craig M. ;
Deng, James Z. ;
Mosser, Scott D. ;
Salvatore, Christopher A. ;
Yu, Sean ;
Roller, Shane ;
Kane, Stefanie A. ;
Vacca, Joseph P. ;
Williams, Theresa M. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (22) :6368-6372
[6]  
BURSTEIN R, 2002, HEADACHE, V42, P390
[7]   Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials [J].
Cady, RK ;
Sheftell, F ;
Lipton, RB ;
O'Quinn, S ;
Jones, M ;
Putnam, DG ;
Crisp, A ;
Metz, A ;
McNeal, S .
CLINICAL THERAPEUTICS, 2000, 22 (09) :1035-1048
[8]   Randomized, controlled trial of telcagepant for the acute treatment of migraine [J].
Connor, K. M. ;
Shapiro, R. E. ;
Diener, H. -C. ;
Lucas, S. ;
Kost, J. ;
Fan, X. ;
Fei, K. ;
Assaid, C. ;
Lines, C. ;
Ho, T. W. .
NEUROLOGY, 2009, 73 (12) :970-977
[9]   The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin [J].
Czirják, B ;
Tóth, ZE ;
Enyedi, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :18550-18558
[10]  
Dahlof C, 1999, Expert Opin Investig Drugs, V8, P671, DOI 10.1517/13543784.8.5.671
12345678